Misbah Tahir - 02 Mar 2026 Form 4 Insider Report for Maze Therapeutics, Inc. (MAZE)

Reporting relationship: Chief Financial Officer
Issuer ticker: MAZE
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:30:38 UTC
Prior SEC filing: 02 Sep 2025
Source filing: View source filing
Reporting owner signature: /s/ Courtney Phillips, as attorney-in-fact

Key filing fact

Misbah Tahir filed Form 4 for Maze Therapeutics, Inc. (MAZE) on 03 Mar 2026.

Key facts

This page summarizes Misbah Tahir's Form 4 filing for Maze Therapeutics, Inc. (MAZE).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Mar 2026, 16:30.

Change

Previous filing in this sequence was filed on 02 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001787359 Primary reporting owner

Tahir Misbah

Relationship: Chief Financial Officer
Address: C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Signature: /s/ Courtney Phillips, as attorney-in-fact
Signature date: 03 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MAZE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +40,000
Change %
Price: $0.000000
Shares after: 40,000
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 40,000
Exercise price: $45.61
Footnotes: F1

MAZE transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +20,000
Change %
Price: $0.000000
Shares after: 20,000
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The option award shall vest as to 1/48 of the total award monthly, with the first tranche vesting on April 1, 2026, subject to the reporting person's continued service to the Issuer on each vesting date.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.

Footnote F3

The restricted stock unit award shall vest in ratable increments of 1/4 of the total award, with the first tranche vesting on March 1, 2027, and vesting thereafter on the one year anniversary of such date, subject to the reporting person's continued service to the Issuer on each vesting date.

Footnote F4

These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.